Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

51 results about "Ubiquitinated Proteins" patented technology

Novel bis-Benzylidine Piperidone Proteasome Inhibitor with Anticancer Activity

ActiveUS20160106725A1Reduced potencyReducing potencyBiocideOrganic chemistryHuman papillomavirus19S regulatory particle
We describe a bis-benzylidine piperidone, RA190, which covalently binds to the ubiquitin receptor RPN13 (ADRM1) in the 19S regulatory particle and inhibits proteasome function, triggering rapid accumulation of polyubiquitinated proteins. Multiple myeloma lines, even those resistant to bortezomib, were sensitive to RA190 via ER stress-related apoptosis. RA190 stabilized targets of human papillomavirus (HPV) E6 oncoprotein, and preferentially killed HPV-transformed cells. After p.o. or i.p. dosing of mice, RA190 distributed to plasma and major organs excepting brain, and potently inhibited proteasome function in skin and muscle. RA190 administration i.p. profoundly reduced growth of multiple myeloma and ovarian cancer xenografts, and oral RA190 treatment retarded HPV+ syngeneic mouse tumor growth, without impacting spontaneous HPV-specific CD8+ T cell responses, suggesting its therapeutic potential. The bis-benzylidine piperidone RA190 is a new orally-available proteasome inhibitor. Multiple myeloma, cervical and ovarian cancers are particularly sensitive to RA190.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

Anti-tumor ubiquitinated protein and extraction method and application thereof

The invention discloses anti-tumor ubiquitinated protein which is mainly extracted from the following steps: (1) culture of tumor cells: resuscitating cryopreserved tumor cells and culturing the tumor cells according to a conventional culture method; (2) treatment of the tumor cells; and (3) extraction of the ubiquitinated protein. The invention further discloses an extraction method of the anti-tumor ubiquitinated protein as well as application of the anti-tumor ubiquitinated protein in preparing tumor therapeutic vaccines. Compared to the prior art, the protein disclosed by the invention can be used for greatly improving the effect of cross-immuno reaction and improving the inhibitory effect on different types of tumors to a great extent; in addition, the problem that ubiquitinated short-lived protein is fast to degrade is further overcome, and a lot of ubiquitinated protein can be quickly obtained. Finally, the asymmetry between the short-lived protein and the long-lived protein is overcome, the target spots for inducing specific effector cells are increased, and the defect that the anti-tumor vaccines are poor in anti-tumor effect based on the long-lived protein is remedied.
Owner:SOUTHEAST UNIV

METHODS OF PREVENTING AND TREATING VIRAL INFECTIONS BY INHIBITING THE DelSGYLATION ACTIVITY OF OTU DOMAIN-CONTAINING VIRAL PROTEINS

Viruses having an impaired ability to deISGylate ISG15 conjugates, in particular, viral mutants comprising a mutation in the viral genome that reduces or eliminates the ability of the viral OTU domain-containing protein encoded by the viral genome to deISGylate ISG15 conjugates and / or deubiquitinate ubiquitinated proteins and / or deNeddylate Neddylated proteins are disclosed. Such viral mutants may be used in the formulation of immunogenic compositions for inducing an immune response and preventing, managing and / or treating a viral infection. Also disclosed are methods for identifying anti-viral compounds, in particular, methods of identifying compounds that reduce or inhibit the deISGylation activity and / or deubiquitination and / or deNeddylation activity of a viral OTU domain-containing protein. The compounds identified using such methods may be used as antiviral agents for the prevention, treatment and / or management of viral infections.
Owner:MT SINAI SCHOOL OF MEDICINE +1

Inhibitors of deubiquitinating proteases

Disclosed are small molecule inhibitors of deubiquitinating enzymes (DUBs), and methods of using them. Certain compounds display a preference for specific ubiquitin specific proteases (USPs).
Owner:BRANDEIS UNIV

Application of chloroquine to promote spinal cord damage repair

The invention provides an application of chloroquine to promote spinal cord damage repair. Chloroquine can inhibit degradation of ubiquitinated protein I-kB[alpha], so that autophagy regulating inflammation can be inhibited to promote spinal cord damage repair. Degradation of ubiquitinated protein I-kB[alpha] can be regulated according to a reaction mechanism of p62-mediated autophagy regulating inflammation LC3-II-p62-I-kB[alpha]. Chloroquine is further introduced to intervene in degradation of ubiquitinated protein I-kB[alpha].
Owner:慈溪市人民医院医疗健康集团

Method of Decreasing Ubiquitylated Protein Levels

The present invention provides a method of decreasing the level of ubiquitylated protein in a subject, the method comprising administering a heterocyclic compound disclosed herein or a pharmaceutically acceptable salt, hydrate or prodrug thereof to a subject in need thereof.
Owner:RGT UNIV OF CALIFORNIA +1

Artificially constructed hybrid ubiquitin conjugation structure domain polypeptide and application thereof

The invention discloses artificially constructed hybrid ubiquitin conjugation structure domain polypeptide and an application thereof. The hybrid ubiquitin conjugation structure domain polypeptide is formed by connecting at least tow ubiquitin conjugation structures in series, and in all ubiquitin conjugation structure domains forming the hybrid ubiquitin conjugation structure domain polypeptide, at least two ubiquitin conjugation structure domain are different. In addition, the hybrid ubiquitin conjugation structure domain polypeptide can contain tag protein. The experiment shows that the tag protein disclosed by the invention can conjugate ubiquitin molecules and different ubiquitin chains carried in the ubiquitin molecules efficiently without unbiasedness, can improve the enrichment efficiency of on-scale ubiquitin protein, is used for developing efficient ubiquitin protein separation mediums and biologic reagents, and can provide technical methods for regulating in-vivo protein ubiquitination. The polypeptide is significant for prompting human disease sample ubiquitin proteomics study and development of health medicine.
Owner:ACADEMY OF MILITARY MEDICAL SCI

Mutated PCV2 (Porcine circovirus Type 2) virus free from being degraded by ubiquitination proteasome, and preparation method and application thereof

The invention provides a mutated PCV2 (Porcine circovirus Type 2) virus free from being degraded by ubiquitination proteasome, and a preparation method and application thereof. Three loci (164K, 179Kand 191K) of porcine circovirus 2 type (PCV2, GenBank and No. EU366323) strains Cap are mutated, the mutated PCV2 can not be subjected to MKRN1-mediated ubiquitination degrading, in addition, high speed copying can be carried out through infectious clone, and virus price is high than virus price of wild-type PCV2. Through mutated viruses obtained by the infectious clone, the pathogenic mechanism of the PCV2 can be more favorably researched, and a potential control measure is provided for PCV2 outbreak.
Owner:NORTHWEST A & F UNIV

Methods for Selecting Proteins that are Readily Presented as Antigens on Dendritic Cells

The present inventors worked on elucidating the mechanism of antigen cross-presentation by dendritic cells, and revealed that foreign antigens taken up in dendritic cells are degraded by proteasomes after undergoing polyubiquitination. They discovered a positive correlation between the uptake amount of an antigenic protein by dendritic cells or the level of polyubiquitination and the level of antigen presentation of the antigenic protein. Based on these findings, methods were developed for predicting the intensity of cross-presentation of an anti genic protein by measuring the amount of antigenic protein taken up or polyubiquitinated protein. The use of these methods allows selecting antigenic proteins that are readily presented as antigens from among a number of proteins. The methods of the present invention enable suitable cancer immune vaccines to be provided through selection of more suitable cancer-specific proteins.
Owner:MEDICAL & BIOLOGICAL LAB CO LTD +1

Bis-benzylidine piperidone proteasome inhibitor with anticancer activity

ActiveUS9913834B2Reducing potencyElimination of Michael acceptor propertiesOrganic chemistryDipeptide ingredientsHuman papillomavirus19S regulatory particle
We describe a bis-benzylidine piperidone, RA190, which covalently binds to the ubiquitin receptor RPN13 (ADRM1) in the 19S regulatory particle and inhibits proteasome function, triggering rapid accumulation of polyubiquitinated proteins. Multiple myeloma lines, even those resistant to bortezomib, were sensitive to RA190 via ER stress-related apoptosis. RA190 stabilized targets of human papillomavirus (HPV) E6 oncoprotein, and preferentially killed HPV-transformed cells. After p.o. or i.p. dosing of mice, RA190 distributed to plasma and major organs excepting brain, and potently inhibited proteasome function in skin and muscle. RA190 administration i.p. profoundly reduced growth of multiple myeloma and ovarian cancer xenografts, and oral RA190 treatment retarded HPV+ syngeneic mouse tumor growth, without impacting spontaneous HPV-specific CD8+ T cell responses, suggesting its therapeutic potential. The bis-benzylidine piperidone RA190 is a new orally-available proteasome inhibitor. Multiple myeloma, cervical and ovarian cancers are particularly sensitive to RA190.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

Ubiquitin chain solid phase detection method and application

The invention relates to a high-efficiency sensitive and unbiased detection method for protein ubiquitin modification in a bio-sample. Artificial synthesis polypeptide formed by two different ubiquitin combination domains in series and including tag protein (GST) in the end N serves as a detection agent. Compared with commercial ubiquitin antibody, the provided detection agent and solid phase detection method can identify 8 different ubiquitin chains formed by ubiquitin molecules in an efficient and unbiased way, the endogenous ubiquitin chain of the bio-sample can be detected without bias, and the detection sensitivity for ubiquitin protein can be improved substantially.
Owner:BEIJING PROTEOME RES CENT

Application of ubiquitination pathway related factor in regulating and controlling functions of regulatory T cell

The invention relates to an application of a ubiquitination pathway related factor in regulating and controlling functions of a regulatory T cell. Specifically, the invention relates an application ofthe ubiquitination pathway related factor and an agonist or an antagonist thereof in preparing a preparation or a reagent for regulating FOXP3 or the regulatory T cell, wherein the ubiquitination related factor is selected from gene coding proteins USP44 and USP7 of a ubiquitination protein family. The novel regulatory factor provided by the invention, by regulating transcriptional regulatory activity of the FOXP3 on a target gene thereof, can regulate and control the regulatory T cell and the balance of an immune system.
Owner:INST PASTEUR OF SHANGHAI CHINESE ACADEMY OF SCI

Application of Ube3a-ubiquitinated protein phosphatase 2A (PP2A) activating factor, namely tyrosine phosphatase activating factor (PTPA), for treating Angelman syndrome and autism

The invention relates to application of an Ube3a-ubiquitinated protein phosphatase 2A (PP2A) activating factor, namely a tyrosine phosphatase activating factor (PTPA), for treating Angelman syndrome and autism. The invention discloses new pathogenesis of Angelman syndrome and / or autism or other related diseases; that is to say, lack or over-expression of Ube3a results in abnormal activity of the tyrosine phosphatase activating factor (PTPA) on the protein phosphatase 2A (PP2A). Thus, the factors can be used as targets for developing drugs to alleviate or treat Angelman syndrome and / or autism or other related diseases. The factors can also be used as markers for diagnosing and assessing Angelman syndrome and / or autism or other related diseases.
Owner:CENT FOR EXCELLENCE IN BRAIN SCI & INTELLIGENCE TECH CHINESE ACAD OF SCI

Modified Bach1 gene and application thereof

ActiveCN109517826ARegulation of pluripotencyRegulate self-renewalGenetically modified cellsUnknown materialsNODALProteinase activity
The invention relates to a modified Bach1 gene and an application thereof to pluripotency, self-updating, proliferation, reprogramming and differentiation of a stem cell. Due to the modification of the Bach1 gene of a transcription factor, the BACH1 protein activity or expression of the cell is inhibited or increased, and furthermore, the cell interacts with a deubiquitinated protease Usp7, a pluripotent factor Nanog, Sox2 and / or Oct4, a PRC2 complex, a Wnt / beta-catenin signal channel and / or an Nodal / Smad2 / 3 signal channel, so that the self-updating, proliferation and / or differentiation of thestem cell are regulated.
Owner:FUDAN UNIV

His-Vx3-eGFP protein-nano aluminum covalent coupling ubiquitinated protein containing carbon-nitrogen bonds as well as extraction method and application thereof

The invention discloses a His-Vx3-eGFP protein-nano aluminum covalent coupling ubiquitinated protein containing carbon-nitrogen bonds as well as an extraction method and application thereof. The ubiquitinated protein is prepared through the following steps of: forming a conjugate of His-Vx3-eGFP protein and modified nano aluminum by virtue of carbon-nitrogen double bonds and incubating the conjugate and a treated tumor cell lysis solution. Compared with the prior art, obtained alpha-Al2O3-His-Vx3-eGFP is stable in property, is capable of greatly improving the ubiquitinated protein collection effect and simplifying experiment operation; in addition, the defect that adjuvants are added in use of an existing ubiquitinated protein vaccine is overcome.
Owner:SOUTHEAST UNIV

Application of E3 ubiquitination protein ligase UBR5 in preparation of tumor diagnosis or prognosis evaluation kit

PendingCN111912985APrecise riskAccurate Prognosis PredictionMaterial analysisProgression-free survivalUbiquitinated Proteins
The invention relates to the field of biotechnology and medical diagnosis, in particular to application of E3 ubiquitination protein ligase UBR5 in preparation of a renal clear cell carcinoma diagnosis or prognosis evaluation reagent or kit and a corresponding detection kit. Researches find that the expression of E3 ubiquitination protein ligase UBR5 molecules in patients with renal clear cell carcinoma is generally reduced, the expression level of the E3 ubiquitination protein ligase UBR5 molecules is remarkably related to prognosis of the patients, and the total lifetime (OS) and progression-free lifetime (PFS) of the patients with renal clear cell carcinoma can be better predicted by combining the expression of UBR5.
Owner:SHANGHAI CITY PUDONG NEW AREA GONGLI HOSPITAL

Fusion protein and application thereof to construction of system for screening coronavirus 3CL protease inhibitor

ActiveCN111875709APreserve Structural-Functional PropertiesEasy to detectCompound screeningApoptosis detectionUbiquitinated ProteinsEngineering
The invention discloses a fusion protein and an application thereof to construction of a system for screening a coronavirus 3CL protease inhibitor. The invention firstly provides the fusion protein. The fusion protein is formed by fusing a ubiquitination protein at an N end and a protein with a reporting function at a C end through a 3CL protease restriction enzyme cutting site amino acid fragment, wherein the 3CL protease restriction enzyme cutting site amino acid fragment is an amino acid fragment which can be recognized by 3CL protease and can be subjected to restriction enzyme cutting. A system for screening the coronavirus 3CL protease inhibitor is constructed by utilizing the fusion protein, an encoding gene of the fusion protein, a carrier containing the fusion protein or recombinant cells for expressing the fusion protein, and the system is convenient and rapid, is simple to operate and has good specificity and sensitivity; by utilizing the system, the coronavirus 3CL proteaseinhibitor can be conveniently and effectively screened, the screening mechanism is clear, the speed is high, the action effect is visual, the universality is high, the repeatability is good, the falsepositive rate is low, and the system has a good application prospect in screening of the coronavirus 3CL protease inhibitor.
Owner:SUN YAT SEN UNIV

Method for determining depression, kit for analyzing serotonin transporter, and kit for analyzing ubiquitinated serotonin transporter in blood

[Problem] To provide: a method for utilizing a novel marker, including a method for determining depression; and a kit for analyzing an ubiquitinated serotonin transporter.[Solution] A method for determining depression, comprising a step of analyzing the proportion of an ubiquitinated serotonin transporter in a blood sample collected from a subject; and a kit for analyzing an ubiquitinated serotonin transporter in blood, which comprises an ubiquitinated protein collector material and an anti-serotonin transporter antibody and is used for the analysis of the proportion of an ubiquitinated serotonin transporter in a collected blood sample.
Owner:MEIJO UNIVERSITY

Method of decreasing ubiquitylated protein levels

The present invention provides a method of decreasing the level of ubiquitylated protein in a subject, the method comprising administering a heterocyclic compound disclosed herein or a pharmaceutically acceptable salt, hydrate or prodrug thereof to a subject in need thereof.
Owner:RGT UNIV OF CALIFORNIA +1

Trim72 as potential therapeutic target for als through ubiquitinating mutant fus protein

Provided is a pharmaceutical composition comprising a scavenger, wherein the scavenger is used for clearing away mutant FUS. A method for treating or preventing or alleviating ALS is also provided.
Owner:神济昌华(北京)生物科技有限公司

Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases

The invention relates to new compounds with low cytotoxicity for blocking the ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders, autoimmune disorders and metabolic disorders.
Owner:CALGENT BIOTECHNOLOGY CO LTD

Application of ubiquitin-binding domain fusion protein in detection and separation of ubiquitination protein

The invention relates to a method for utilizing ubiquitin-binding domain (UBD) fusion protein to separate and detect ubiquitination protein. The principle is that a fusion protein is constructed by using an affinity label and a ubiquitin-binding domain. The fusion protein can be expressed in colon bacillus, purified and fixed on a gel particle through the ligand of the affinity label. Mixed culture is carried out on the gel particle with the ubiquitin-binding domain fusion protein and lysate of cell or tissue, and the ubiquitination protein in the lysate can be separated out through precipitation. On the aspect of the detection of ubiquitination protein, the method disclosed by the invention is higher in efficiency, detection capacity and flexibility compared with the current antibody immune precipitation detection method. Moreover, on the aspect of economic benefit, the cost of detecting ubiquitination protein in the invention is extremely lower than that of expensive antibody immune precipitation method; and the method can be applied to fundamental research of protein ubiquitination and the detection of ubiquitination protein in medical diagnosis test.
Owner:JIANGSU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products